Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

From the RNS of 24/12/12.

On 24/12/12 the NHS set out it's minimum requirements for Intra-Operative Fluid Management.

As we all know there were cash incentives to NHS Trusts if they had everything geared up by 31st march 2013 by having put measures in place to meet the criteria set out in order to qualify for the release of any 2013/14 CQUIN funding.

So with all the advantages, such as lower death rates, lower re-admissions, less in patient days, less suffering coupled with a now cash incentive, we still see little movement in the UK.

We now know that expectations in the US are 2 to 2.5 years and not much moving anywhere else, although we do have comments re Spain perhaps starting to push things, but we have had such promising news so many times.

So it does bare the question re further funding not just or more trainers and hopefully possible increase in production sales costs, but for the general running of the company.

I won't go over old ground re Deltex going it alone but I would like to see more fire in the belly of management.

In a reply from Ewan a few months ago re my comments regarding a far more aggressive approach to NHS none take up IE leaks to the media, the reply was that such an approach was being considered (aggressive but no leaks to the media).

I have see little of this approach, but with the NHS Trusts still sitting around all day either overseeing more and more hospital foul-ups or moving papers from one pending tray to the other, I can't see how a very aggressive approach could make things worse.

For me, if something ground breaking does not appear before year end, I am out as I have been caught too many times in the past allowing heart to rule head, a dangerous game indeed.

Organised in partnership with Cenkos Securities and Shares magazine, the second Innovators & Investors Forum will take place on 4th February 2014 at the Business Design Centre, London N1.

The event aims to showcase up to 40 leading innovative and imaginative technology-led firms and to bring them together with the investment community. It combines both a company expo and an educational conference where delegates learn about a range of investment opportunities.

REGISTER NOW

Why attend?

This event gives you a platform to meet under one roof up to 40 technology-led companies, hear their messages during presentation seminars and engage in discussions with them on their stands.

The event is supported with an extensive conference program, including keynote speakers and company presentations.



Companies already confirmed for the 4th February 2014 include:

Allocate Software
Angle
Avanti Communications
Bango
Bond International Software
Brady
Cenkos Securities
CML Microsystems
Deltex Medical
Earthport
Eleco
Enables IT
Escher Group Holdings
Filtronic
Forbidden Technologies
Globo
Imperial Innovations
incadea
InternetQ
ITM Power
KBC Advanced Technologies
Kromek Group
Optimal Payments
Plastics Capital
Quindell
Regenersis
Rightster
StatPro
Transense Technologies


CONFERENCE AGENDA

The following session is dedicated to a mix of institutional investor and private investors.

11:40 Company presentation - Colin Miles, VP, Corporate Relations - InternetQ

11:55 Company presentation - Hank Uberoi, CEO - Earthport

12:10 Company presentation - Quindell

12:25 Company presentation - Dr Nigel Pitchford, Chief Investment Officer - Imperial Innovations

12:40 Lunch

The afternoon sessions are dedicated to private investors.

14:00 Keynote address - Richard Penny, Senior Fund Manager - Legal and General UK Alpha Trust

14:15 Russ Mould, Editor - Shares Magazine

14:30 Company presentation - Kromek Group

14:45 Company presentation - Joel Leonoff, President & CEO - Optimal Payments

15:00 Company presentation

15:15 Company presentation - Charlie Muirhead, CEO and Founder - Rightster

15:30 Company presentation - Caroline Brown, Executive Director & CFO - KBC Advanced Technologies

15:45 Coffee

16:15 Company presentation - Andrew Fabian, Group Finance Director - StatPro

16:30 Company presentation

16:45 Company presentation

17:00 Company presentation - Jonathan O’Connell, CFO - Escher Group Holdings

17:15 Company presentation - ITM Power

17:30 Close

The exhibition will be open from 10:45 to 17:30.

Coffee / lunch will be served within the exhibition.


This agenda is subject to change and alterations. More companies to be announced soon.

REGISTER NOW

The exhibition will be open from 10:45 to 17:30.

Coffee / lunch will be served within the exhibition.



This agenda is subject to change and alterations. More companies to be announced soon.



EXHIBITION

The exhibition will be open from 10:45 to 17:30.

Coffee / lunch will be served within the exhibition.



Dress code: business attire




VENUE
Business Design Centre
52 Upper Street
Islington
London N1 0QH

http://www.businessdesigncentre.co.uk/

Access map: http://www.businessdesigncentre.co.uk/VisitingUs

Closest tube station: Angel (3 min. walk) - Northern Line





SPONSOR


Cenkos Securities is an independent specialist securities firm focused on UK small and mid-cap companies.
We aim to be entrepreneurial, whilst seeking to establish long-term relationships with corporate and institutional clients.
Our directors and partners have on average more than 25 years' experience in the UK securities market. They have pioneered and led some of the most successful and innovative transactions in the UK securities market over the last decades.

REGISTER NOW

Haven't posted for a while, but I have a question re todays RNS.

If Deltex are to sell an alternative system to their own they will have to answer questions as to how their own system compares, surely any increase of the USCOM1A in the UK will mean less sales of the CardioQ.
Also what message does his send to potential CardioQ customers, does is say that Deltex lack confidence in the CardioQ.

How can pushing a competitors product be good for the sales of your own product.
I appreciate there is a reciprocal agreement, but does anyone else read this as desperation on the part of Deltex.

Not trying to 'have a go' as I have been accused of in the past, but would appreciate opinions.

Sorry, wrong thread.

RNS.

Joint broker must mean they are looking to release a few contracts or similar good news as if not a joint broker will be a waste of money.

Come on Deltex give us some news worth putting out, although I appreciate as per the rules any broker news has to be released.

No mattter how people argue the pro's and con's of Deltex,the sp is now at it's lowest for 3 years and only a couple of pence higher than it's 10 low.

Whilst appreciating that sales have steadily increased over the last couple of years with accelerated growth over the last 12 months something earth shattering has to happen, otherwise the sp will soon be into single figures.

RNS.

The extended agreement with NHS Supply Chain has to be the way to go.

Let others push sales, whilst Deltex concentrate on their products.

Third party sales can often push more firmly than a direct line pitch.

well, yes. But NHS is in cost-cutting mood, so I guess they call the price.

It would be nice if the sp rose every year - this time 2013 was 3p up ( that's nearly 25%), and the same story the year before....
I hear Execs saying "All is good", but the Market isn't listening...

On the whole all is looking good, although it is relying on more promises of things to come, but I suppose that is the way of the beast.

The only possible negative part that rouses my suspicious mind is 'The NHS has ended its 2013 plan to make compliance with high impact innovations a pre-qualification criterion for CQUIN payments and moved towards embedding adoption of IOFM into the NHS standard contract. It will take time for the new approach to roll-out across the NHS but we believe it will help to underpin continuing growth momentum towards the end of this year and into 2015.'

This to me shows the lack of teeth that the NICE have as it appears that if NHS Trusts do not go along with the rules, then plan B comes into play.
This is fine as long as the same lack of co-operation from the Trusts regarding plan A does not carry over to plan B.

But on summing up the RNS, it does look as if the small holding I have left will make me a few quid, although I expect this to take at least another couple of years.

Petition to stop short selling.

Well worth a read.

http://epetitions.direct.gov.uk/petitions/62851

RNS,

Often placings/offers are not a good sign, but looking at the reasons for this cash call I for one will be taking up the offer.

Whilst only now holding a token amount of shares, at 11p I feel that it is a reasonable offer, this of course depends on the actions of the sp between now and the offer.

I do of course appreciate that the extra shares will dilute any value of holdings to around the 11p level.

Also this has to be the final cash all, as I doubt that any further such calls will be accepted.

After receiving my letter re the offer this morning I have changed my mind from my previous post, due to the latest date of receipt being the 4th of June, so with the weekend, to be sure of receipt I will have to send off acceptance by Sat at the latest.

The question is, with the sp now at 11.00p bid and 11.25p offer (I can buy at 11.10p) do I chance it, wait and see if the sp drops even lower or not bother at all.

When the offer came out mid price was 11.60p, dropping from 13.78p the day before (news obviously leaked).

Just looking at facts, I doubt if I will bother, as if the offer price is as poor a bargain as it is starting to look at a drop today of .25p, the sp after the 4th could drop even further.

Not an easy decision, as although I believe the reasons behind the offer are genuine and solid, if I can buy at lower than 11p in the near future, waiting looks the best bet.

It looks like they have miscalculated the offer price, but I don't think it's a case for falling on any swords quite yet, but if within a couple of months we see no benefit from the share offer, IE at least a couple of contracts or/and a noticeable increase in probe use, then that sword might be swung by a few shareholders, (I might change my user name to Damocles).

I would also like to know which company was paid to come up with the offer price of 11p, obviously they did not earn their fee.

Todays RNS.

No getting away from it that things, albeit slowly, are looking up.

Can't believe that there is no activity whatsoever today, MM's holding deals back from release today perhaps!

Buys now going through at 10.75p, so looks like those who bought in the offer overpaid.

Not gloating as some no doubt will, usually of course those who never get things wrong and I admit to being tempted re the offer.

Today's RNS.

Two new none execs, both with plenty of experience in the areas Deltex are looking for and also with good connections in the field, this can only be good.

Not surprised though that this news is greeted with a falling sp, which goes to show that positive action on the contract front is the only thing that investors are bothered about.

Deleted as pointed out by a poster on a different site, my facts were wrong.

Apologies to those that may have been mislead.

Large Sell.

0811 hrs, sell of 500,000 went through at bottom price, I wonder how much the seller lost.

Would like to see at least something trickling through from the Physician payment increase in the USA that was announced on 16 June.

I appreciate that the announcement was less than a month ago, but the sp is only 2p above its all time low.

Yes, I know, patience is still required, but it ain't easy!

Large volume today, all sells and yet the sp finishes level.

Not like Deltex at all!!!!!!

Pre close update.

Excepts.
UK surgical probe sales 13% down due to NHS de-stocking; stronger sales since May.

Q I would like to know what those stronger sales since May are, IE 1%, 2% or what, far too vague.

NHS implementation drive re-launch expected in H2 2014

Q Will it work this time.

International surgical probes up 11% and Monitor sales up £150,000 (86%) on stronger export orders, (Hopefully mainly in the USA).

Great, although international probe sales are only up 11%, the 86% increase in Monitor sales will result in a far greater increase in probe sales in the next few months.

So looking good, although due to the general lack of interest in Deltex, I think this will have only a minimal effect on the SP.